drugset
drugset / Trial / NCT05067140

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

NCT05067140 ↗

Phase 1/2 Active not recruiting 152 enrolled Novartis Pharmaceuticals
RandomizedSequentialOpen-labelTreatment

Summary

A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth alone or in combination with abiraterone in men with metastatic prostate cancer.

Timeline

Start
2021-09-02
Primary completion
2027-05-25
Completion
2027-05-25

Drugs

EvaluationDrugModalityDoseRoute
Subject ARV-766 Unknown — Oral
Subject Abiraterone acetate Small molecule — Oral

Indications

metastatic prostate carcinoma